Given the crosstalk between p53 and NF-κB, we hypothesized that treatment of prostate cancer cells with BA upregulates the expression of p53, thereby leading to NF-κB inactivation, and promoting apoptosis. The gene discussed is TP53; the disease is prostate carcinoma.